Research & Publications
Dr. Corbin's overarching research goal is to combine neuroimaging and cancer biology to improve both the quality of life and longevity of patients suffering from neuro-oncologic disease.
Extensive Research Description
His clinical research career began as a medical student at Yale, and he then earned a student research fellowship to study at the Massachusetts General Hospital. He trained as a neurologist at the University of California, San Francisco and then completed Neuro-Oncology Fellowship at Stanford University. At Stanford, he led a study employing positron emission tomography (PET)/MRI in patients with glioblastoma who received bevacizumab.
He was recruited back to Yale to develop the program in metabolic imaging in neuro-oncology. With his colleagues at the Yale Magnetic Resonance Research Center, he has deployed deuterium metabolic imaging (DMI) in patients with primary brain tumors. He has since developed a multi-modality imaging technique using PET and magnetic resonance spectroscopy (MRS) called the Warburg Index. He and his colleagues aim to measure metabolic changes in gliomas with a particular mutation in isocitrate dehydrogenase (IDH).
Brain; Brain Neoplasms; Metabolism